Par Drugs And Chemicals Limited has informed the Exchange regarding Board meeting held on August 07, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals' Board, at its meeting on August 7, 2025, approved the unaudited standalone financial results for the quarter ended June 30, 2025. Revenue from operations rose to ₹2,604.64 lakh from ₹2,260.56 lakh in the same quarter last year, a growth of about 15%. Total income stood at ₹2,788.31 lakh versus ₹2,267.91 lakh YoY. Profit before tax climbed to ₹447.78 lakh from ₹338.50 lakh, while profit after tax grew to ₹332.81 lakh from ₹253.31 lakh, a jump of roughly 31% YoY. Basic and diluted EPS stood at ₹2.70, up from ₹2.06 in Q1 FY25. The statutory auditor issued an unmodified limited review report with no qualifications. The Board also noted the renewal of its ₹161 lakh banking facility with Kotak Mahindra Bank at the same existing limit, and reported zero pending investor complaints for the quarter.
Strong double-digit growth in both revenue and profit signals improving operational performance, likely a positive for shareholders. The clean auditor report, unchanged banking limit, and no investor grievances indicate stability with no negative red flags in this quarter.